New York, NY -- (SBWire) -- 09/08/2017 --In addition, lichen sclerosus may result in red or purple colored bruises, skin becomes more prone to tear, itching and bleeding. The main cause of lichen sclerosus is still unknown, it is believed to be caused by hyper-immunity reactions or by hormonal imbalance. An individual with previous skin destruction around genital or anal region, are more susceptible to develop lichen sclerosus.
The growth of lichen sclerosus treatment market is mainly driven by the increasing prevalence of immune system disorders, especially in females. In addition, hormonal misbalance is a general symptom in females undergoing menopause and are more liable to develop lichen sclerosus, and thereby, boosts the growth of lichen sclerosus market.
However, the growth of lichen sclerosus market can be hampered owing to the lack of awareness among the population. The majority of population considers lichen sclerosus as a general infection which can be eradicated by itself. Moreover, other factors such as no availability of proper treatment or no exact drug formulation available in the market for treating lichen sclerosus can impede the growth of lichen sclerosus treatment market.
Geographically, global lichen sclerosus treatment market can be segmented into North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. North America holds the largest market share, followed by Europe owing to more sophisticated healthcare infrastructure and ease of availability of treatment options. In addition, other factors such as favorable reimbursement policies also boosts the growth of lichen sclerosus treatment market in North America.
Asia-Pacific region is estimated to grow at a rapid rate over the forecast period owing to factors such as presence of large population base in this region, including large geriatric population, and increasing healthcare facilities, and increasing investment by the public or private bodies, which propels the growth of lichen sclerosus treatment market.
However, regions such as Latin America, Middle East and Africa show a steady growth during the forecast year due to the lack of awareness about the disease and its treatment, and dearth of skilled professional in these regions, but, these regions are anticipated to provide ample opportunities during the forecast period.
Request for more detailed information (TOC And Sample): https://www.persistencemarketresearch.com/samples/17971
Some of the market participants in the global lichen sclerosus treatment are AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sandoz AG (Novartis AG), Sanofi S.A., Valeant Pharmaceuticals, and Zylera Pharmaceuticals.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
About Persistence Market Research
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Why Lichen Sclerosus Treatment Market Is Projected to Witness a Staggering Growth During 2017-2025
Lichen sclerosus is a chronic disorder of the skin, affecting the genital and anal areas. However, in some serious cases, they may appear on upper body such as arms and breast regions.